Abstract
Purpose
To develop a novel nanoparticle drug delivery system consisting of chitosan and glyceryl monooleate (GMO) for the delivery of a wide variety of therapeutics including paclitaxel.
Methods
Chitosan/GMO nanoparticles were prepared by multiple emulsion (o/w/o) solvent evaporation methods. Particle size and surface charge were determined. The morphological characteristics and cellular adhesion were evaluated with surface or transmission electron microscopy methods. The drug loading, encapsulation efficiency, in vitro release and cellular uptake were determined using HPLC methods. The safety and efficacy were evaluated by MTT cytotoxicity assay in human breast cancer cells (MDA-MB-231).
Results
These studies provide conceptual proof that chitosan/GMO can form polycationic nano-sized particles (400 to 700 nm). The formulation demonstrates high yields (98 to 100%) and similar entrapment efficiencies. The lyophilized powder can be stored and easily be resuspended in an aqueous matrix. The nanoparticles have a hydrophobic inner-core with a hydrophilic coating that exhibits a significant positive charge and sustained release characteristics. This novel nanoparticle formulation shows evidence of mucoadhesive properties; a fourfold increased cellular uptake and a 1000-fold reduction in the IC50 of PTX.
Conclusion
These advantages allow lower doses of PTX to achieve a therapeutic effect, thus presumably minimizing the adverse side effects.
References
J. A. Ajani, et al. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J. Sci. Am. 4(4):269–274 (1998).
B. B. Rogers. Taxol: a promising new drug of the ‘90s. Oncol. Nurs. Forum 20(10):1483–1489 (1993).
A. K. Singla, et al. Paclitaxel and its formulations. Int. J. Pharm. 235(1–2):179–192 (2002).
B. D. Tarr, and S. H. Yalkowsky. A new parenteral vehicle for the administration of some poorly soluble anti-cancer drugs. J. Parenter. Sci. Technol. 41:31–33 (1987).
T. C. Chao, et al. Paclitaxel in a novel formulation containing less Cremophor EL as first-line therapy for advanced breast cancer: a phase II trial. Invest. New Drugs 23(2):171–177 (2005).
H. Gelderblom, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37(13):1590–1598 (2001).
D. Friedland, et al. Hypersensitivity reactions from taxol and etoposide. J. Natl. Cancer Inst. 85(24):2036 (1993).
N. K. Ibrahim, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 8(5):1038–1044 (2002).
W. J. Gradishar. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin. Pharmacother. 7(8):1041–1053 (2006).
M. Socinski. Update on nanoparticle albumin-bound paclitaxel. Clin. Adv. Hematol. Oncol. 4(10):745–746 (2006).
J. Lee Villano, et al. Abraxane induced life-threatening toxicities with metastatic breast cancer and hepatic insufficiency. Invest. New Drugs 24(5):455–456 (2006).
A. Bernkop-Schnurch, et al. Thiomers: preparation and in vitro evaluation of a mucoadhesive nanoparticulate drug delivery system. Int. J. Pharm. 317(1):76–81 (2006).
F. Zheng, et al. Chitosan nanoparticle as gene therapy vector via gastrointestinal mucosa administration: results of an in vitro and in vivo study. Life Sci. 80(4):388–396 (2007).
A. M. De Campos, et al. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm. 224(1–2):159–168 (2001).
G. Sandri, et al. Nanoparticles based on N-trimethylchitosan: evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models. Eur. J. Pharm. Biopharm. 65(1):68–77 (2007).
A. Moore, et al. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res. 64(5):1821–1827 (2004).
F. Cui, et al. Preparation and characterization of mucoadhesive polymer-coated nanoparticles. Int. J. Pharm. 316(1–2):154–161 (2006).
K. A. Howard, et al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. 14(4):476–484 (2006).
H. Takeuchi, et al. Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm. Res. 13(6):896–901 (1996).
H. Takeuchi, et al. Novel mucoadhesion tests for polymers and polymer-coated particles to design optimal mucoadhesive drug delivery systems. Adv. Drug Deliv. Rev. 57(11):1583–1594 (2005).
J. Thongborisute, et al. The effect of particle structure of chitosan-coated liposomes and type of chitosan on oral delivery of calcitonin. J. Drug Target 14(3):147–154 (2006).
S. Jauhari, and A. K. Dash. A mucoadhesive in situ gel delivery system for paclitaxel. AAPS PharmSciTech. 7(2):E53 (2006).
J. Panyam, and V. Labhasetwar. Targeting intracellular targets. Curr. Drug Deliv. 1(3):235–247 (2004).
A. K. Dash, et al. X-ray powder diffractometric method for quantitation of crystalline drug in microparticulate systems. I. Microspheres. J. Pharm. Sci. 91(4):83–990 (2002).
Y. Wu, et al. Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate. Int. J. Pharm. 295(1–2):235–245 (2005).
F. Q. Hu, et al. Shell cross-linked stearic acid grafted chitosan oligosaccharide self-aggregated micelles for controlled release of paclitaxel. Colloids Surf. B Biointerfaces 50(2):97–103 (2006).
J. Hyung Park, et al. Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: in vivo biodistribution and anti-tumor activity. Biomaterials 27(1):119–126 (2006).
J. H. Kim, et al. Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel. J. Control Release 111(1–2):228–234 (2006).
F. Maestrelli, et al. A new drug nanocarrier consisting of chitosan and hydoxypropylcyclodextrin. Eur. J. Pharm. Biopharm. 63(2):79–86 (2006).
S. A. Agnihotri, et al. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J. Control Release 100(1):5–28 (2004).
C. Prego, et al. Chitosan-PEG nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree. J. Control Release 111(3):299–308 (2006).
M. Garcia-Fuentes, et al. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur. J. Pharm. Sci. 25(1):133–143 (2005).
E. S. Lutton. Phase behavior of aqueous systems of monoglycerides. J. Am. Oil Chem. Soc. 42(12):1068–1070 (1965).
G. Garg, and S. Saraf. Cubosomes: an overview. Biol. Pharm. Bull. 30(2):350–353 (2007).
S. Ganguly, and A. K. Dash. A novel in situ gel for sustained drug delivery and targeting. Int. J. Pharm. 276(1–2):83–92 (2004).
Y. Sadhale, and J. C. Shah. Glyceryl monooleate cubic phase gel as chemical stability enhancer of cefazolin and cefuroxime. Pharm. Dev. Technol. 3(4):549–556 (1998).
M. Uner. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Pharmazie 61(5):375–386 (2006).
P. M. Bummer. Physical chemical considerations of lipid-based oral drug delivery–solid lipid nanoparticles. Crit. Rev. Ther. Drug Carrier Syst. 21)(1):1–20 (2004).
P. R. Lockman, et al. Nanoparticle technology for drug delivery across the blood–brain barrier. Drug Dev. Ind. Pharm. 28(1):1–13 (2002).
S. J. Douglas, et al. Nanoparticles in drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 3(3):233–261 (1987).
H. Takeuchi, et al. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv. Drug Deliv. Rev. 47(1):39–54 (2001).
F. Shikata, et al. In vitro cellular accumulation of gadolinium incorporated into chitosan nanoparticles designed for neutron-capture therapy of cancer. Eur. J. Pharm. Biopharm. 53(1):57–63 (2002).
Acknowledgements
These studies were supported by a Department of Defense Concept Award BC045664.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Trickler, W.J., Nagvekar, A.A. & Dash, A.K. A Novel Nanoparticle Formulation for Sustained Paclitaxel Delivery. AAPS PharmSciTech 9, 486–493 (2008). https://doi.org/10.1208/s12249-008-9063-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-008-9063-7